AAAAAA

   
Results: 1-17 |
Results: 17
Prognostic impact of proteolytic factors (Urokinase-Type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy
Authors: Harbeck, N Alt, U Berger, U Kruger, A Thomssen, C Janicke, F Hofler, H Kates, RE Schmitt, M
Citation: N. Harbeck et al., Prognostic impact of proteolytic factors (Urokinase-Type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy, CLIN CANC R, 7(9), 2001, pp. 2757-2764
Clinical relevance of the plasminogen activator inhibitor type 1 - a multifaceted proteolytic factor
Authors: Harbeck, N Kruger, A Sinz, S Kates, RE Thomssen, C Schmitt, M Janicke, F
Citation: N. Harbeck et al., Clinical relevance of the plasminogen activator inhibitor type 1 - a multifaceted proteolytic factor, ONKOLOGIE, 24(3), 2001, pp. 238-244
Do we need better prognostic factors in node-negative breast cancer? Pro
Authors: Thomssen, C Janicke, F Kaufmann, M Scharl, A Hayes, DF
Citation: C. Thomssen et al., Do we need better prognostic factors in node-negative breast cancer? Pro, EUR J CANC, 36(3), 2000, pp. 293-298
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer
Authors: Prechtl, A Harbeck, N Thomssen, C Meisner, C Braun, M Untch, M Wieland, M Lisboa, B Cufer, T Graeff, H Selbmann, K Schmitt, M Janicke, F
Citation: A. Prechtl et al., Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer, INT J B MAR, 15(1), 2000, pp. 73-78
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer
Authors: Harbeck, N Alt, U Berger, U Kates, R Kruger, A Thomssen, C Janicke, F Graeff, H Schmitt, M
Citation: N. Harbeck et al., Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer, INT J B MAR, 15(1), 2000, pp. 79-83
The role of anthracyclines in the adjuvant therapy of breast cancer
Authors: Thomssen, C
Citation: C. Thomssen, The role of anthracyclines in the adjuvant therapy of breast cancer, ONKOLOGIE, 23, 2000, pp. 7-11
HER-2/neu as a predictive marker in breast cancer
Authors: Konecny, G Pegram, M Untch, M Thomssen, C Janicke, F Hepp, H Slamon, DJ
Citation: G. Konecny et al., HER-2/neu as a predictive marker in breast cancer, GEBURTSH FR, 60(12), 2000, pp. 609-619
Procedures after first-line treatment of ovarian cancer
Authors: Thomssen, C
Citation: C. Thomssen, Procedures after first-line treatment of ovarian cancer, ONKOLOGIE, 22, 1999, pp. 27-28
Human parvovirus B19-associated disease in bone marrow transplantation
Authors: Schleuning, M Jager, G Holler, E Hill, W Thomssen, C Denzlinger, C Lorenz, T Ledderose, G Wilmanns, W Kolb, HJ
Citation: M. Schleuning et al., Human parvovirus B19-associated disease in bone marrow transplantation, INFECTION, 27(2), 1999, pp. 114-117
Diagnosis and treatment of cervical squamous cell carcinoma
Authors: Riethdorf, L Park, TW Thomssen, C
Citation: L. Riethdorf et al., Diagnosis and treatment of cervical squamous cell carcinoma, PATHOLOGE, 20(1), 1999, pp. 42-49
An algorithm for endometrial meta- and hyperplasia
Authors: Loning, T Reusch, U Thomssen, C
Citation: T. Loning et al., An algorithm for endometrial meta- and hyperplasia, PATHOLOGE, 20(1), 1999, pp. 56-62
An algorithm for the clinical and pathomorphological study of endometrial carcinoma
Authors: Loning, T Reusch, U Thomssen, C
Citation: T. Loning et al., An algorithm for the clinical and pathomorphological study of endometrial carcinoma, PATHOLOGE, 20(1), 1999, pp. 63-71
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
Authors: Harbeck, N Thomssen, C Berger, U Ulm, K Kates, RE Hofler, H Janicke, F Graeff, H Schmitt, M
Citation: N. Harbeck et al., Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse, BREAST CANC, 54(2), 1999, pp. 147-157
High dose treatment of mammary carcinoma. "Wait and see" is the reaction to the results of the randomized studies presented at the ASCO 1999 in Atlanta
Authors: Hoffken, K Diehl, V Kanz, L Possinger, K Zander, A Kreienberg, R Bender, HG Elling, D Jackisch, C Luck, HJ Mobus, V Nitz, U Thomssen, C Untch, M Gaisser, A
Citation: K. Hoffken et al., High dose treatment of mammary carcinoma. "Wait and see" is the reaction to the results of the randomized studies presented at the ASCO 1999 in Atlanta, GYNAKOLOGE, 32(8), 1999, pp. 655-655
Case report on leiomyomatosis in pelvic lymph nodes during oestrogen substitution
Authors: Henschen, S Gronewold, M Thomssen, C Riethdorf, L Janicke, F
Citation: S. Henschen et al., Case report on leiomyomatosis in pelvic lymph nodes during oestrogen substitution, GEBURTSH FR, 59(1), 1999, pp. 37-40
Risk group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow up
Authors: Harbeck, N Dettmar, P Thomssen, C Berger, U Ulm, K Kates, R Hofler, H Janicke, F Graeff, H Schmitt, M
Citation: N. Harbeck et al., Risk group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow up, BR J CANC, 80(3-4), 1999, pp. 419-426
Prognostic and predictive factors in breast cancer
Authors: Untch, M Kahlert, S Thomssen, C Janicke, F
Citation: M. Untch et al., Prognostic and predictive factors in breast cancer, GYNAKOLOGE, 31(12), 1998, pp. 1067-1074
Risultati: 1-17 |